| 肖莉莎,姚青青,段世军,周 妮,郭 琳,张蓓蕾.子宫内膜异位症的激素治疗对卵巢纤维化和卵巢储备的影响[J].现代生物医学进展英文版,2022,(9):1681-1686. |
| 子宫内膜异位症的激素治疗对卵巢纤维化和卵巢储备的影响 |
| The Effect of Hormone Therapy for Endometriosis on Ovarian Fibrosis and Ovarian Reserve |
| Received:September 06, 2021 Revised:September 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.09.016 |
| 中文关键词: 子宫内膜异位症 卵巢纤维化 卵巢储备 激素治疗 |
| 英文关键词: Endometriosis Ovarian fibrosis Ovarian reserve Hormone therapy |
| 基金项目:国家自然科学基金项目（81260387/H1621） |
|
| Hits: 797 |
| Download times: 397 |
| 中文摘要: |
| 摘要 目的：探讨子宫内膜异位症的激素治疗对卵巢纤维化和卵巢储备的影响。方法：选取2019年9月-2021年8月西安国际医学中心医院收治的86例子宫内膜异位症患者，将其随机分为四组（A、B1、B2、C），A组未接受任何激素治疗，B1组和B2组接受炔诺酮孕激素治疗，C组接受促性腺激素释放激素（GnRH）治疗。比较四组24个月复发率、复发期间肿瘤直径大小、抗苗勒激素（AMH）和促卵泡激素（FSH）水平以及血清转化生长因子-β1（TGF-β1）和平滑肌肌动蛋白（α-SMA）的表达。结果：与治疗前相比，A组斑点样出血以及痛经情况未发生变化（P>0.05），B1、B2和C组斑点样出血升高，痛经情况降低（P<0.05）；治疗后，B1、B2和C组较A组斑点样出血升高、痛经情况降低，C组较B1、B2组升高（P<0.05）。与治疗期间对比，四组子宫内膜异位症复发率均发生变化（P<0.05）。在治疗期间，与A组相比，B1组、B2组和C组子宫内膜异位症复发率降低，且B1组、B2组较C组降低；在随访期间，B1组、B2组复发率低于C组（P<0.05）。与治疗期间相比，A组随访期间子宫内膜瘤直径比较无差异（P>0.05），B1、B2和C组增大（P<0.05）。B1、B2和C组较A组子宫内膜瘤直径减小（P<0.05），而C组较B1、B2组增大（P<0.05）。与治疗前相比，四组治疗后血清FSH水平升高，血清AMH水平降低（P<0.05）；治疗后，B1、B2和C组较A组血清FSH水平降低，AMH水平升高（P<0.05）。各组治疗后较治疗前TGF-β1和α-SMA的蛋白表达降低（P<0.05）；治疗后B1、B2和C组较A组TGF-β1和α-SMA蛋白表达水平降低（P<0.05）。结论：与GnRH相比，孕激素可能是子宫内膜异位症术后卵巢储备和纤维治疗的更好选择。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of hormone therapy for endometriosis on ovarian fibrosis and ovarian reserve. Methods: A total of 86 patients with endometriosis admitted to the Xi'an International Medical Center Hospital from September 2019 - August 2021 were selected and randomly divided into four groups(A, B1, B2 and C). Group A did not receive any hormone therapy, group B1 and B2 received norethinyl progesterone therapy, and group C received GnRH therapy. The recurrence rate at 24 months, tumor diameter during recurrence, FSH and AMH levels, and serum TGF-β1 and α-SMA protein expressions were compared among the four groups. Results: Compared with before treatment, there was no change in spotty bleeding and dyspenorrhea in group A (P>0.05), spot bleeding increased and dyspenorrhea decreased in groups B1, B2 and C(P<0.05); After treatment, spotty bleeding and dyspenorrhea were increased and decreased in groups B1, B2 and C compared with group A, and increased in group C compared with group B1 and B2 (P<0.05). The relapse was recorded after 12 months of treatment and 12 months of follow-up. Endometriosis recurrence rates changed in all four groups compared with the treatment period (P<0.05). During treatment, the recurrence rate of endometriosis in groups B1, B2 and C was lower than that in group A, and B1 and B2 groups were lower than that in group C. During follow-up, the recurrence rate of group B1 and B2 was lower than that of group C (P<0.05). Compared with treatment, there was no difference in endometrial tumor diameter during follow-up in group A (P>0.05), increased in groups B1, B2 and C (P<0.05). The diameter of endometrioma in groups B1, B2 and C was smaller than that in group A(P<0.05), and increased in group C compared with groups B1 and B2(P<0.05). Compared with before treatment, serum FSH levels were increased and serum AMH levels were decreased in four groups after treatment(P<0.05); After treatment, serum FSH levels in groups B1, B2 and C were lower than those in group A, and serum AMH levels were higher (P<0.05). The protein expressions of TGF-β1 and α-SMA decreased after treatment compared with before treatment(P<0.05); After treatment, TGF-β1 and α-SMA protein expressions in groups B1, B2 and C were lower than those in group A(P<0.05). Conclusion: Compared with GnRH, progesterone may be the uterus A better choice for ovarian reserve and fiber therapy after endometriosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
